Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: MIKE DUBIS who wrote (2365)	11/10/1997 11:01:00 PM
From: Zebra 365	Read Replies (3) \| Respond to of 23519

I'm sure that would be the case, except we are talking about the same drug, alprostadil, just a different delivery system. Injection vs. trans-mucosal. Now I have no doubt that injection is a more potent way to deliver alprostadil. And my issue is really not with Padma-Nathan's ability to become the spokesman for every drug and system out there. The Pharm companies PR people have probably planted, ie. press released and pre-written a lot of this coverage. The Dr is respected for his research and this is a LOT of money we are talking about, not for Dr Padma-Nathan but for this sector of medicine and for these companies (and their shareholders lest we forget). I am just very frustrated that we have an excellent delivery system that sits between oral and injectable (no reason that Viagra (sindelafil) would not work better and be safer via trans-urethral method MUSE) and we're being treated like Ross Perot's "Crazy Aunt in the Basement", no one's talking about us. Not really running down Padma-Nathan, but I want equal mention from someone who put his name on almost all the MUSE studies. Also, I'm outlining the marketing strategy for our non-existant PR presence, ie. forget publicizing the problem and focus on the treatment distinctions, MUSE is longer lasting and has fewer potential side effects than oral, and NO Needles. Zebra

To: MIKE DUBIS who wrote (2365)	11/11/1997 6:12:00 AM
From: James Baker	Respond to of 23519

md:<<<Zebra: I thought your last post was well done but I must ask if it is it possible that PADMA NATHAN now feels the drugs he mentioned are superior to VVUS?>>> Mike Mike Mike - pd is a PAID consultant to whatever companies is paying him today. To leave MUSE out shows that this is a company press release trying to position themselves for the marketing of viagra - not to be a medical/scientific discrouse. Zebra - you have done a great job putting that piece together. PLEASE send it to VIVUS, Nina, the CEO individually and anyone else that you find addresses for. Jim